Thursday, January 15, 2015

ហេតុផលដែលសម្ពាធឈាមគួរតែវាស់ពីដៃទាំងសងខាង (Reasons That Blood Pressure Shall Be Measured From Both Arms)

ដកស្រង់ចេញពីអត្ថបទ New Study Presents Evidence that Blood Pressure Should Be Measured in Both Arms (PDF) 


ការសិក្សាថ្មីបានបង្ហាញអំពីភស្តុតាង "សម្ពាធឈាមគួរតែវាស់ពីដៃទាំង ២ (ទាំងសងខាង) ។

ការស្រាវជ្រាវថ្មីមួយនេះបានចុះផ្សាយនៅក្នុងទិនានុប្បវត្តិវេជ្ជសាស្ត្រអាមេរិកប្រចាំខែមីនា បានបង្ហាញអោយឃើញអំពីទំនាក់ទំនងនៃសម្ពាធឈាមស៊ីស្តូលីកខុសគ្នារវាងដៃទាំងសងខាង ដែលត្រូវបានកំណត់ ១០ មីលីម៉ែត្របារត ឬ ខ្ពស់ជាងនេះ នឹងអាចបង្កើនហានិភ័យបញ្ហាសរសៃឈាម បេះដូងនាពេលអនាគត។

សម្ពាធឈាមស៊ីស្តូលីកSystolic Blood Pressure (ឬ ជាតួលេខនៃសម្ពាធឈាមខាងលើរូបភាពទី ១) គឺ ជាការកន្រា្តក់នៃបេះដូង និង ការជំរុញបញ្ចូនឈាមតាមសរសៃឈាមទៅកាន់រាងកាយរបស់យើង ។

សម្ពាធឈាមដៃស្តូលីក (daɪˈæstəliː) - Diastolic Blood Pressure (ឬ ជាតួលេខនៃសម្ពាធឈាមខាងក្រោមរូបភាពទី ២) គឺ ជាសម្ពាធក្នុងសរសៃឈាម ខណះដែលបេះដូងសម្រាកចន្លោះចង្វាក់នីមួយៗ ។


New Study Presents Evidence that Blood Pressure Should Be Measured in Both Arms

Difference in Interarm Blood Pressure Linked to Greater Risk of Future Cardiovascular Events,

Reports The American Journal of Medicine
Philadelphia, PA, February 25, 2014 – As heart disease continues to be one of the leading causes of death in the United States, practitioners and patients alike are looking for ways to cut risk factors and identify new clues to assist with early detection. New research published in the March issue of The American Journal of Medicine suggests that there is an association between a difference in interarm systolic blood pressure and a significant increased risk for future cardiovascular events, leading researchers to recommend expanded clinical use of interarm blood pressure measurement.

While blood pressure is a widely used medical metric, most measurements are taken only using one arm. Measuring interarm blood pressure involves taking two readings, one for each arm. Increased interarm systolic blood pressure differences are defined as 10 mmHg or greater, and while a link between interarm blood pressure and cardiovascular risk was suspected, little data existed to support the hypothesis until now.

This new study examined 3,390 participants aged 40 years and older from the Framingham Heart Study. All subjects were free of cardiovascular disease at baseline, but investigators found that participants with higher interarm systolic blood pressure differences were at a much higher risk for future cardiovascular events than those with less than a 10 mm Hg difference between arms.

“In this large prospective, community based cohort of middle-age men and women free of cardiovascular disease, an increased interarm systolic blood pressure difference was found to be present in nearly 10% of individuals and is associated with increased levels of traditional cardiovascular risk factors,” explains lead investigator Ido Weinberg, MD, Institute for Heart Vascular and Stroke Care, Massachusetts General Hospital, Boston. 

“Furthermore, an increased interarm systolic blood pressure difference is associated with an increased risk for incident cardiovascular events, independent of traditional cardiovascular risk factors.”

Researchers also found that participants with elevated interarm blood pressure difference were older, had a greater prevalence of diabetes mellitus, higher systolic blood pressure, and a higher total cholesterol level.

According to these findings, investigators suggest practitioners should consider including blood pressure readings in both arms in order to get the most accurate readings possible and detect any differences in interarm blood pressure. “Even modest differences in clinically-measured systolic blood pressures in the upper extremities reflect an increase in cardiovascular risk,” says Weinberg. “This study supports the potential value of identifying the interarm systolic blood pressure difference as a simple clinical indicator of increased cardiovascular risk.”

# # #


"The Systolic Blood Pressure Difference Between Arms and Cardiovascular Disease in the Framingham. Heart Study,” by Ido Weinberg, Philimon Gona, Christopher J. O’Donnell, Michael R. Jaff, Joanne M. Murabito (DOI, appears in The American Journal of Medicine, Volume 127/Issue 3 (March 2014) published by Elsevier.

Full text of the article is available to credentialed journalists upon request. Contact Jane Grochowski at 215-239-3712 or to obtain copies. Journalists wishing to interview the authors should contact Colleen Marshall at 617-726-0275 or


The American Journal of Medicine (, known as the “Green Journal,” is one of the oldest and most prestigious general internal medicine journals published in the United States. It has an Impact Factor of 4.768, which ranks it 13 out of 151 General and Internal Medicine titles according to the 2012 Journal Citation Reports® published by Thomson Reuters.

AJM, the official journal of The Association of Professors of Medicine, a group comprised of chairs of departments of internal medicine at 125-plus U.S. medical schools, publishes peer-reviewed, original scientific studies that have direct clinical significance. The information contained in this article in The American Journal of Medicine is not a substitute for medical advice or treatment, and the Journal recommends consultation with your physician or healthcare professional. AJM is published by Elsevier.

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet ( and Cell (, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect (, Scopus (, SciVal (, Reaxys (, ClinicalKey ( and Mosby’s Suite (, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively. 

A global business headquartered in Amsterdam, Elsevier ( employs 7,000 people
worldwide. The company is part of Reed Elsevier Group plc (, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL. 

No comments:

Post a Comment